Global prices of Cyanoacetamide API increased in July 2025 for the third straight month because of tight pharma demand, lower availability from maintenance shutdowns, and increased feedstock prices. Indian and Chinese production bottlenecks, hikes in cyanoacetic acid prices, and robust trade confidence in Europe and the US also helped fuel the bullish trend.. The trend is projected to continue in August as well with minimal supply relief and ongoing cost pressures sustaining high prices.
The global Cyanoacetamide Active Pharmaceutical Ingredient (API) market followed a steady growth pattern through July 2025 on the back of a combination of firm demand fundamentals, tightening supply conditions, and rising feedstock costs. The participants in the Asian, European, and North American markets reported ongoing price increases for Cyanoacetamide throughout the month, the third consecutive monthly increase, and preliminary indicators suggest that the trend will continue during August.
The prime motivator for Cyanoacetamide’s price hike in July was increased demand in the pharmaceutical industry, mostly for the intermediates that are synthesized for making active compounds in oncology and central nervous system (CNS) drug products. Major API manufacturers in India, China, and parts of Europe said they received additional orders from domestic as well as export markets, as downstream formulators tried to stockpile adequate volumes of Cyanoacetamide ahead of anticipated seasonal procurement cycles. This pre-loading of demand imposed additional pressure on already lean inventories.
On the supply side, production limitations in key centers of Cyanoacetamide manufacturing were the key to supporting the bullish sentiment. In China, a number of Cyanoacetamide production facilities executed planned maintenance shutdowns towards the end of Q2, running into early July, suppressing exportable volumes available for sale. From China, intermittent logistics bottlenecks due to port congestion and inland sluggishness pushed delivery lead times for major markets in Europe and North America. Furthermore, regulatory tightening in a few Chinese provinces regarding environmental compliance continued to limit operational run rates for Cyanoacetamide’s smaller producers, effectively capping spot supply.
Feedstock costs also had their share in the increase. The price of cyanoacetic acid—Cyanoacetamide’s preferred feedstock—registered huge increases over July, goaded by high acetic acid and sodium cyanide prices on the global market. Higher energy prices, especially in Asia and the Middle East, further compound production expenses, prompting suppliers to pass on the cost burden to buyers. Currency fluctuations, particularly the depreciation of the Chinese yuan against the US dollar, added to export price adjustments for international buyers. On a trade basis, the European market saw firm bids from Asian sellers of Cyanoacetamide amidst firm end-user demand for the specialty chemical and pharmaceutical business segments. The US market also saw a bullish tone, with domestic buyers securing forward contracts for Cyanoacetamide at higher levels to hedge against potential price risks over the next couple of months.
Ahead, sentiment continues to be in favor of higher gains in August 2025. Continuing robust pharmaceutical demand for Cyanoacetamide, residual supply shortages from Asia, and continued toughness in feedstock prices should continue to drive the positive trend. Market analysts observe that barring a sharp deceleration in raw material costs or an unexpected recovery in production capacities, Cyanoacetamide API prices should hold on to their high levels with scope for incremental hikes as Q3 advances.
